Head to Head Survey: Viridian Therapeutics (NASDAQ:VRDN) and Fractyl Health (NASDAQ:GUTS)

Fractyl Health (NASDAQ:GUTS) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Fractyl Health and Viridian Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90,000.00	962.86	-$140.95 million	($0.88)	-0.62
Viridian Therapeutics	$70.85 million	32.92	-$342.60 million	($3.37)	-6.11

Fractyl Health has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Fractyl Health and Viridian Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1	1	3	0	2.40
Viridian Therapeutics	1	0	12	0	2.85

Fractyl Health currently has a consensus price target of $5.50, suggesting a potential upside of 910.29%. Viridian Therapeutics has a consensus price target of $38.69, suggesting a potential upside of 87.92%. Given Fractyl Health’s higher possible upside, equities research analysts plainly believe Fractyl Health is more favorable than Viridian Therapeutics.

Profitability

This table compares Fractyl Health and Viridian Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

Volatility and Risk

Fractyl Health has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Summary

Fractyl Health beats Viridian Therapeutics on 7 of the 12 factors compared between the two stocks.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.